GlobeNewswire by notified

Sydbank’s 2022 Annual Report

Share

Company Announcement No 03/2023
1 March 2023

Sydbank’s 2022 Annual Report

Record-breaking profit due to high activity and rising interest rates

The Sydbank Group’s 2022 financial statements show a profit before tax of DKK 2,405m compared to DKK 1,764m in 2021. The increase of DKK 641m is primarily attributable to a rise in earnings of DKK 751m and a drop in costs (core earnings) of DKK 137m set off against the effect of a lower reversal of impairment charges of DKK 316m. Profit before tax equals a return of 18.9% p.a. on average equity.

Profit for the year represents DKK 1,901m against DKK 1,411m in 2021, equal to a return on average equity of 14.8% after tax. At the beginning of 2022 profit after tax was projected to be in the range of DKK 1,150-1,450m.

CEO Karen Frøsig comments on the record-breaking profit:
- It is very good news that we can deliver the best result in the Bank’s history. We have improved our performance because we have succeeded in increasing interest income significantly while at the same time reducing costs.

Karen Frøsig comments on the development in interest income:
- The effect of the Danish central bank’s 4 interest rate hikes during H2 2022 is clearly reflected in the Bank’s net interest income, which is now at a substantially higher level. Net interest income has been greatly influenced by the rise in loans and advances as well as by higher interest payments on the Bank’s significant deposit surplus, which has so far earned negative interest.

Board chairman Lars Mikkelgaard-Jensen comments:
- It is highly satisfactory that the record-breaking profit and the Bank’s strong capital position allow us to distribute an all-time high dividend of DKK 16.77 per share, equal to 50% of profit for 2022. Following the dividend payout the Bank will continue to be well capitalised.

Outlook for 2023

  • Negative growth is projected for the Danish economy.
  • Core income is expected to be higher than in 2022.
  • Costs (core earnings) are projected to be higher than in 2022.
  • Impairment charges are forecast to represent a minor expense.
  • Non-recurring costs are expected to be in the range of DKK 50-60m.
  • Profit after tax is expected to be in the range of DKK 1,900-2,200m.
  • The outlook is subject to uncertainty and depends on financial market developments and macroeconomic factors which may affect eg the level of impairment charges.

Additional information
Jørn Adam Møller, Deputy Group Chief Executive, tel +45 74 37 20 30
Susanne Ingemann Faber, Press Manager, tel +45 26 29 11 29

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial3.6.2023 23:00:00 CEST | Press release

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois. The Phase 1 trial successfully met primary endpoints for safety and tolerability of EVX-01 in metastatic melanoma patients

BW Offshore: Short-term contract extension for Espoir Ivoirien3.6.2023 16:39:00 CEST | Press release

Short-term contract extensionfor Espoir Ivoirien BW Offshore has signed a short-term extension for the lease and operation of the FPSO Espoir Ivoirien in order to discuss a potential purchase of the FPSO by the client. The firm period has been extended until 9 June 2023. For further information, please contact: Ståle Andreassen, CFO, +47 91 71 86 55 Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore: BW Offshore engineers innovative floating production solutions. The Company has a fleet of 8 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

Jobindex A/S meddeler sin hensigt om afnotering og tilbud fra Danielsen 2 ApS til aktionærerne om køb af deres aktier til 1.900 kr. pr. aktie2.6.2023 20:16:00 CEST | pressemeddelelse

Selskabsmeddelelse nr. 6 / 2023 København, Danmark 2. juni 2023 – Jobindex A/S (“Jobindex” eller “Selskabet”), meddeler, at Jobindex i dag har besluttet at lade Selskabets aktier slette fra handel og officiel notering fra Nasdaq First North Growth Market Denmark (“Nasdaq First North”) og bemyndiget adm. direktør Kaare Danielsen til at indgive anmodning herom til Nasdaq Copenhagen A/S inden den 1. oktober 2023 samt at Danielsen 2 ApS (“Tilbudsgiver”) fremsætter et frivilligt ureguleret offentligt købstilbud på 1.900 kr. pr. aktie (det “Offentlige Købstilbud”) til alle aktionærer i Jobindex med undtagelse af Tilbudsgiver og Selskabet for så vidt angår egne aktier. For aktionærerne i Jobindex A/S betyder dette, at man har valget imellem at: Acceptere det Offentlige Købstilbud, der indebærer en præmie på ca. 8,6% ift. lukkekursen pr. 2. juni 2023 og en præmie på ca. 9,7% ift. de sidste 12 handelsdages volumenvægtede gennemsnitskurs (VWAP); ellerFortsætte uændret som aktionær i Jobindex A/S

Nokia Corporation: Repurchase of own shares on 02.06.20232.6.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 2 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.06.2023 Espoo, Finland – On 2 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,6953.83CEUX1,1353.84AQEU1,6303.81TQEX1,9403.81Total367,4003.83 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and end

BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release

Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m